|
Synonyms: LP-168 | LP168
rocbrutinib is an approved drug
Compound class:
Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor. Code name-to-INN was formally disclosed in 2024 [3]. Rocbrutinib binds covalently to wild-type BTK and non-covalently to mutated BTK proteins, including BTKC481 and gatekeeper mutations.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Rocbrutinib (LP-168) was advanced to clinical assessment for potential to treat B cell malignancies. First approval was granted by China's NMPA in June 2026 [2], to treat BTKC481S mutant positive relapsed/refractory CLL/SLL. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05917964 | A Food Effect Study of LP-168 Tablets in Healthy Subjects | Phase 1 Interventional | Guangzhou Lupeng Pharmaceutical Company LTD. | ||
| NCT04993690 | A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma | Phase 1 Interventional | Guangzhou Lupeng Pharmaceutical Company LTD. | ||
| NCT05716087 | A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma | Phase 2 Interventional | Guangzhou Lupeng Pharmaceutical Company LTD. | ||